NTLA
$13.48
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyre...
Recent News
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
This run could be short-lived.
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound
Why Intellia Therapeutics (NTLA) Is On Investors’ Radar Intellia Therapeutics (NTLA) has drawn attention after a recent stretch of positive returns, with the stock up over the month, the past 3 months, and over the past year. For investors, this performance is sitting alongside a business that reports US$67.671 million in revenue and a net loss of US$412.694 million, reflecting the costs of its clinical stage gene editing programs and partnership agreements. See our latest analysis for...
Roblox initiated, Target upgraded: Wall Street's top analyst calls
Roblox initiated, Target upgraded: Wall Street's top analyst calls
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The growth investor kicked off this week by buying up some hard-hit stocks.
Intellia Advances Gene Editing Programs Toward Hereditary Angioedema Commercial Reality
Intellia Therapeutics (NasdaqGM:NTLA) has completed enrollment in its phase 3 HAELO trial of lonvo-z for hereditary angioedema. The FDA has lifted the clinical hold on Intellia’s MAGNITUDE-2 trial for ATTR amyloidosis, clearing the way for enrollment to resume. The company is progressing commercialization plans in the U.S. for lonvo-z as a potential one-time gene-editing treatment for hereditary angioedema. Intellia Therapeutics, a gene editing company listed on NasdaqGM:NTLA, is moving its...